Kazia Prices $40M Underwritten Offering at $15.50/ADS with Warrants
KZIA has more than doubled off its 52-week low of $4.86 on elevated volume (5.6× avg).
Summary
Kazia priced a $40 million underwritten offering of ADSs and warrants at $15.50 per ADS, a discount to the prior close, to fund expansion of its paxalisib clinical programs.
Key Events · Financing and Capital Events · KZIA
-
Underwritten Offering Priced at $15.50/ADS
Kazia priced 2,276,800 ADSs at $15.50 each plus accompanying warrants, generating approximately $40 million in gross proceeds. The offering price represents a discount to the $16.90 last reported sale price on August 27, 2026.
-
Warrant Structure Adds Potential Upside
The offering includes 2,243,478 Series A warrants (exercise $17.825) and 2,064,000 Series B warrants (exercise $19.375), which could generate up to $80 million in additional proceeds if exercised. Warrants expire 30 days after specific clinical milestones or five years from issuance.
-
Net Proceeds Fund Clinical Expansion
Approximately $37 million in net proceeds will fund expansion of paxalisib into HR+/HER2- breast cancer, colorectal cancer, and early-stage high-risk TNBC, plus continued enrollment in the Phase 1b TNBC trial.
-
Dilution Impact
Immediately after closing, Kazia expects 7,774,439,234 ordinary shares outstanding, rising to 9,928,178,234 on a fully as-adjusted basis if all warrants are exercised — a 28% increase from the current 6,484,439,234 shares.
Analysis · KZIA · Life Sciences
Kazia finalized terms of its underwritten offering, pricing 2,276,800 ADSs at $15.50 each — a discount to the $16.90 last reported sale price on August 27, 2026. The deal includes Series A and Series B warrants with exercise prices of $17.825 and $19.375 respectively, which could bring in up to $80 million more if exercised. Net proceeds of approximately $37 million will fund expansion of paxalisib clinical programs into HR+/HER2- breast cancer, colorectal cancer, and early-stage TNBC. The offering comes immediately after the company reported 100% clinical benefit in six evaluable Stage IV TNBC patients, capitalizing on the positive data to raise capital at a favorable valuation. Existing shareholders face dilution from the new ADSs plus potential warrant exercises, but the capital extends runway for multiple clinical expansion programs.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KZIA was trading at $13.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $155.2M. The 52-week trading range was $4.86 to $17.40. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.